The conversation is about finding a reasonably priced shampoo with piroctone olamine in the US. The user is cautious about trying new or smaller brands.
A user stopped oral finasteride after 7 years due to decreased libido and switched to topical finasteride and minoxidil. Others shared similar experiences and discussed alternatives like dutasteride and topical treatments.
The user is considering adding liposomal dutasteride to their hair loss treatment, which currently includes topical finasteride and minoxidil. They are exploring different concentrations and application frequencies to enhance hair retention and are also planning to continue using Rogaine.
The user experienced severe side effects from oral finasteride, including sexual dysfunction and mental health issues, and switched to topical finasteride, which led to significant hair shedding. They are considering other treatments like RU58841 or topical dutasteride and are advised to check testosterone levels and address potential underlying health issues.
Alfatradiol is often discussed at a 1% concentration, but studies typically use 0.025%. Some users report success using it as a topical treatment alongside other hair loss treatments like finasteride.
RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.
A 35-year-old is considering Breezula, Pyrilutamide, or topical finasteride/dutasteride to protect against hair loss while on testosterone replacement therapy (TRT). They currently use finasteride, oral minoxidil, and dutasteride but experienced increased hair shedding with TRT.
A user has been taking a chewable combination of finasteride, minoxidil, and vitamins daily for three months without side effects or shedding. They are considering adding derma rolling to their routine.
A user shared their positive hair regrowth progress after using 1 mg oral finasteride and 5% minoxidil foam twice daily for four months. They experienced initial shedding but no side effects, and plan to switch to a cheaper minoxidil foam brand.
A 31-year-old man shared his hair growth progress from July 2024 to March 2026 using oral finasteride (1mg) and minoxidil (2.5mg), with no significant side effects. He is considering switching treatments but is advised to continue with the current regimen due to its effectiveness.
A 23-year-old has been using finasteride 5mg daily since age 19 and added dutasteride 0.5mg twice a week to prevent hairline recession. They report no side effects and credit early treatment for maintaining their hair.
Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.
Topical dutasteride 0.05% is reported to outperform oral finasteride with minimal side effects, but concerns about study bias exist due to company funding. Some users report mixed results with topical dutasteride, noting issues with skin penetration and systemic absorption.
The user experienced sexual side effects from a topical finasteride and minoxidil combo and stopped using it after three weeks. They plan to use foam minoxidil nightly to slow hair loss and seek alternative treatments that don't affect sexual health.
The user shared their 4-month progress using oral finasteride and topical minoxidil, with a specific application routine. They adjust the minoxidil application to manage costs, applying it daily with variations in quantity and additional tretinoin on certain days.
PP405 significantly improves hair density, outperforming finasteride, with 31% of users seeing over 20% improvement in four weeks. Concerns exist about its availability, cost, and long-term effects.
The post is about whether there is any additional benefit to using alfatradiol or other estrogen treatments for hair loss if someone is already using finasteride, dutasteride, or an androgen receptor inhibitor like RU58841, pyrithione zinc, or fluridil.
The user has been using dutasteride and finasteride but still experiences hair loss and high DHT levels. They plan to try topical finasteride and RU58841 while continuing dutasteride to see if topicals are more effective.
Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.
The user experienced hair thinning after using finasteride, minoxidil, and vitamin chewables for three months and considered switching to oral minoxidil and dutasteride. The texture change in chewables was noted, but the thinning might be due to other factors like switching to dutasteride or effects from hormone replacement therapy.
The user recommends a thickening clay as a great pre-styling product for hair volume and texture, despite its poor hold. They also mention using finasteride and express skepticism about the effectiveness of a shampoo containing saw palmetto and caffeine.
KX-826 failed Phase III trials due to high placebo effects, patient compliance issues, COVID-19 side effects, and detection method deviations. KX-826 is now marketed as a cosmetic and approved for combination with Minoxidil.
Finasteride and dutasteride are still available in the EU, with a warning about potential suicidal thoughts. The benefits of these treatments are deemed greater than the risks.
The user resumed using topical finasteride after a two-week break and will update on side effects like water retention and gynecomastia in a month. They are also starting DIM and zinc.
The conversation is about a topical spray containing finasteride, minoxidil, and tretinoin, with users discussing its effectiveness compared to more established brands. One user mentions using a product with 5% minoxidil, 0.15% finasteride, and 0.15% tretinoin.
A user shared their successful 50-day progress using oral minoxidil and finasteride for hair loss. They plan to switch to dutasteride after six months for potentially better results.
Finasteride, Minoxidil, Bioneer CosmeRNA, Technoderma, Kintor, Hope, Breezula, and Follicum treatments showed increases in hair count, with Technoderma showing the highest increase at 24.3 hairs/cm². Amplifica has not yet published results.
The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.
In Austria, finasteride prescriptions are restricted due to suicide risk concerns, with new prescriptions only for current users. Alternatives like topical finasteride, dutasteride, and online purchases face legal challenges.